Literature DB >> 20142755

Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.

Jeong-Hoon Lee1, Goh Eun Chung, Su Jong Yu, Sang Youn Hwang, Joon Suk Kim, Hwi Young Kim, Jung-Hwan Yoon, Hyo-Suk Lee, Nam-Joon Yi, Kyung-Suk Suh, Kuhn Uk Lee, Ja-June Jang, Yoon Jun Kim.   

Abstract

GOAL: In this study, we attempted to evaluate the prognosis of combined hepatocellular and cholangiocarcinoma (cHCC-CC) with comparison to hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CC).
BACKGROUND: The prognosis of cHCC-CC has not been fully elucidated. In this study, we attempted to evaluate the prognosis of cHCC-CC with comparison to HCC and CC. STUDY: Consecutive patients who underwent curative resection for cHCC-CC at a single tertiary care center in Korea and their age, sex, and Child-Turcotte-Pugh class matched HCC and CC patients were included. We evaluated time-to-recurrence (TTR) and overall survival (OS) of cHCC-CC cases and compared them with HCC and CC patients.
RESULTS: Thirty cHCC-CC, 60 HCC, and 60 CC patients were included. For cHCC-CC group, the median TTR and OS were 5.4 and 18.0 months. After adjustment for confounding factors, the cHCC-CC group had a shorter TTR than did HCC group [relative risk (RR), 2.76; P<0.001] and CC group (RR, 2.00; P=0.013), and a shorter OS than HCC group (RR, 4.70; P<0.001). Compared with the each stage I diseases, cHCC-CC had shorter TTR than HCC (RR, 4.59; P=0.001) and CC (RR, 2.74, P=0.015) and shorter OS than HCC (RR, 9.35; P=0.001).
CONCLUSIONS: The results of this study indicated that cHCC-CC had a significantly poorer prognosis than HCC and CC even after curative resection.

Entities:  

Mesh:

Year:  2011        PMID: 20142755     DOI: 10.1097/MCG.0b013e3181ce5dfa

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  50 in total

1.  Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.

Authors:  Ruidong Xue; Lu Chen; Chong Zhang; Masashi Fujita; Ruoyan Li; Shu-Mei Yan; Choon Kiat Ong; Xiwen Liao; Qiang Gao; Shota Sasagawa; Yanmeng Li; Jincheng Wang; Hua Guo; Qi-Tao Huang; Qian Zhong; Jing Tan; Lisha Qi; Wenchen Gong; Zhixian Hong; Meng Li; Jingmin Zhao; Tao Peng; Yinying Lu; Kiat Hon Tony Lim; Arnoud Boot; Atushi Ono; Kazuaki Chayama; Zemin Zhang; Steve George Rozen; Bin Tean Teh; Xin Wei Wang; Hidewaki Nakagawa; Mu-Sheng Zeng; Fan Bai; Ning Zhang
Journal:  Cancer Cell       Date:  2019-05-23       Impact factor: 31.743

2.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

Review 3.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

4.  Hepatocellular carcinoma: clinical study of long-term survival and choice of treatment modalities.

Authors:  Ke-Tong Wu; Cun-Chuan Wang; Li-Gong Lu; Wei-Dong Zhang; Fu-Jun Zhang; Feng Shi; Chuan-Xing Li
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

5.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

6.  Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification.

Authors:  Dong-Hwan Jung; Shin Hwang; Seung-Mo Hong; Yong-Kyu Chung; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gil-Chun Park; Han Chu Lee; Young-Suk Lim; Eun Sil Yu; Sung-Gyu Lee
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

7.  Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with combined hepatocellular-cholangiocarcinoma.

Authors:  Chae Hong Lim; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee; Seung Hyup Hyun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-02       Impact factor: 9.236

Review 8.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

9.  Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review.

Authors:  Ming Chi; Kaidi Mikhitarian; Chanjuan Shi; Laura W Goff
Journal:  Gastrointest Cancer Res       Date:  2012-11

10.  Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.

Authors:  Jung Il Lee; Jin-Woo Lee; Joon Mee Kim; Ja Kyung Kim; Hyun Jung Chung; Young Soo Kim
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.